SPARK CRC
ActiveSummary
SPARK CRC has been active since 2016 and the Belgian State Gazette contains no insolvency or warning signals. The 2024 annual accounts show equity of €710,179 and a net result of €114,807. Equity is growing by ~30.4% per year across the filed fiscal years. Its solvency ranks better than 40% of 87 sector peers (fiscal year 2024). The computed 12-month bankruptcy probability is 0.6% (low).
Checked score
Score 2024
Axes · tick = 2023
Profitability73▼-4
Solvency49▼-7
Growth78=
Track record100
Bankruptcy probability, 12 months
0.6%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €40,000 at 30 days acceptable
Liquidity tight (current ratio 1.26 against 1.59 in 2023; short-term debt: 7.9% and cash: 1.6% of total assets), and 75.9% of the assets are financed with debt.
Credit check for your own amount and term
Show the recommended maximum : and see how the verdict changes with amount, term and advance.
Signals
Two signals. The signal on the left, the evidence on the right.
+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 21
Relative position
BE, all sectors
reference
Manufacture of basic pharmaceutical products and pharmaceutical preparations (NACE 21)
about 14% more bankruptcies
← fewer bankruptcies
more bankruptcies →
neutral · Filed after the deadline
The financial year that closed on 31-12-2024 was due by 31-07-2025 and was filed on 30-09-2025, 61 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 8 filingsDeviation from the deadline
2025
not confirmed
2024
61 d late
2023
30 d late
2022
71 d late
2021
108 d late
2020
69 d late
2019
3 d early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
This company filed its last 6 accounts on average 56 days after the deadline; the sector median for financial year 2024 is 9 days before the deadline, and 32% of the sector filed late.
Checked, nothing found (1)
History
Go further with this company
How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check How does this company compare with its sector?Sector benchmark What changed in the latest annual accounts?What changed
Your own company? See how customers, suppliers and banks see it and what to improve first.
Investigating this company? Keep it with today's facts in a case file.
Financials · fiscal year 2024, micro schema
In the rankings
#2 company by total assets in Waasmunster, Manufacturing sector#4 company by equity in Waasmunster, Manufacturing sector
Equity
€710,179▲ 19.3%
2023 · €595,372
Total assets
€2.9m▲ 55.1%
2023 · €1.9m
Net result
€114,807▼ 13.1%
2023 · €132,072
Working capital
€61,894▼ 38.1%
2023 · €99,917
Trend over the years
In euros
In per cent
Ratio
In euros
No line ticked in this group.
In per cent
No line ticked in this group.
Ratio
No line ticked in this group.
Untick a line to hide it. Point at a year (or use the arrow keys on the chart) for the exact figures; the table below gives them all.Sector: the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings. Dashed line: the median. Available for Net result, Equity, Total assets, Working capital, Solvency, Current ratio, Return on assets (ROA).
Every figure with its change against the fiscal year before
favourable
unfavourable
Line20202021202220232024
Operating result€180,362▲ 100%€171,685▼ 4.8%€156,840▼ 8.6%€189,502▲ 20.8%€187,103▼ 1.3%
Net result€128,300above the sector's middle half▲ 82.1%€131,257above the sector's middle half▲ 2.3%€121,725above the sector's middle half▼ 7.3%€132,072above the sector's middle half▲ 8.5%€114,807above the sector's middle half▼ 13.1%
Equity€211,118above the sector's middle half▲ 4.9%€342,375above the sector's middle half▲ 62.2%€463,300above the sector's middle half▲ 35.3%€595,372above the sector's middle half▲ 28.5%€710,179above the sector's middle half▲ 19.3%
Total assets€566,291within the sector's middle half▼ 5.7%€800,389above the sector's middle half▲ 41.3%€1.2mabove the sector's middle half▲ 48.6%€1.9mabove the sector's middle half▲ 59.6%€2.9mabove the sector's middle half▲ 55.1%
Debt€355,173▼ 11.1%€458,013▲ 29.0%€726,320▲ 58.6%€1.3m▲ 79.4%€2.2m▲ 71.5%
Working capital€114,625within the sector's middle half▼ 42.6%€217,623above the sector's middle half▲ 89.9%€34,462within the sector's middle half▼ 84.2%€99,917within the sector's middle half▲ 190%€61,894within the sector's middle half▼ 38.1%
Solvency37.3%within the sector's middle half▲ 3.8pp42.8%within the sector's middle half▲ 5.5pp38.9%within the sector's middle half▼ 3.8pp31.4%within the sector's middle half▼ 7.6pp24.1%within the sector's middle half▼ 7.2pp
Current ratio2.60within the sector's middle half▼ 0.953.57within the sector's middle half▲ 0.971.28within the sector's middle half▼ 2.291.59within the sector's middle half▲ 0.321.26within the sector's middle half▼ 0.33
Return on assets (ROA)22.7%above the sector's middle half▲ 10.9pp16.4%above the sector's middle half▼ 6.3pp10.2%within the sector's middle half▼ 6.2pp7.0%within the sector's middle half▼ 3.3pp3.9%within the sector's middle half▼ 3.1pp
above
within
below
the middle half (P25 to P75) of NACE 21, Manufacture of basic pharmaceutical products and pharmaceutical preparations, each year against the same schema; no band under 30 filings.
Turnover and EBIT margin not published: the micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result falls in 2024; 2024 is 1% below 2023.
Balance-sheet composition
2024 in colour, 2023 as the grey bar beneath
Assets €2.9m
Fixed assets
€2.6m ▲ 62.5%
Current assets
€295,934 ▲ 10.3%
Equity and liabilities €2.9m
Equity
€710,179 ▲ 19.3%
Debt
€2.2m ▲ 71.5%
Debt's share of the balance-sheet total rises from 68.6% to 75.9%. Equity and debt are higher.
Key figures and ratios
EBITDA
€279,383▲
2023 · €223,015
Cash flow
€207,087▲
2023 · €165,585
Debt to equity
3.15▲
2023 · 2.19
ROE
16.2%▼
2023 · 22.2%
Interest coverage
5.91▼
2023 · 11.59
Debt ≤ 1 year
€234,040▲
2023 · €168,351
Debt > 1 year
€1.9m▲
2023 · €1.0m
Income taxes
€37,423▼
2023 · €41,599
Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.
Peer companies
Historical observationOf the 4,105 companies that looked in July 2024 the way this one looks now, 1.0% went bankrupt within 24 months and 98% are still going.
- Small
- 10 to 20 years old
- solvency 10 to 30%
- a profit under 5% of the balance sheet
1.0%
went bankrupt
0.9%
stopped otherwise
98%
still going
A further 0.1% stopped, but we cannot tell whether within those 24 months.
For this company itself Checked computes a bankruptcy probability of 0.6% over twelve months; the group does not contradict it.
How reliable is this rule?
Tested on the year before, without using that year itself: the groups of July 2023 gave each of the 497,340 companies of July 2024 its group's bankruptcy share. Expected: 1.6%; actually bankrupt within 24 months: 1.7%.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 1.0% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
The rule ranks well: a company that went bankrupt got a higher share than one that kept going in 74% of comparisons. The level follows the economy: in a year with more bankruptcies, the actual share is higher than the year before.
An observation about 4,105 comparable companies, not a prediction for this company. The sector does not count: the register keeps no sector for companies that stopped, so it would make the outcome look better than it was.
Annual accounts
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Non-recurring operating income76A | - | - | - | €424 | €0 | ▼ 100% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €18,741 | €12,235 | €16,155 | €33,512 | €92,280 | ▲ 175% |
| Other operating charges640/8 | - | €4,317 | €12,526 | €1,750 | €2,339 | ▲ 33.7% |
| Gross operating margin9900 | €201,635 | €188,236 | €185,521 | €224,764 | €281,722 | ▲ 25.3% |
| Operating profit (loss)9901 | €180,362 | €171,685 | €156,840 | €189,502 | €187,103 | ▼ 1.3% |
| Financial income75/76B | - | €5,127 | €10,827 | €3,412 | €12,384 | ▲ 263% |
| Recurring financial income75 | €6,540 | €5,127 | €10,827 | €3,412 | €12,384 | ▲ 263% |
| Financial charges65/66B | - | €4,201 | €7,045 | €19,243 | €47,257 | ▲ 146% |
| Recurring financial charges65 | €12,237 | €4,201 | €7,045 | €19,243 | €47,257 | ▲ 146% |
| Profit (loss) for the period before taxes9903 | €174,664 | €172,610 | €160,622 | €173,672 | €152,230 | ▼ 12.3% |
| Income taxes67/77 | €46,364 | €41,353 | €38,897 | €41,599 | €37,423 | ▼ 10.0% |
| Profit (loss) for the period9904 | €128,300 | €131,257 | €121,725 | €132,072 | €114,807 | ▼ 13.1% |
| Profit (loss) for the period to be appropriated9905 | €128,300 | €131,257 | €121,725 | €132,072 | €114,807 | ▼ 13.1% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total assets20/58 | €566,291 | €800,389 | €1.2m | €1.9m | €2.9m | ▲ 55.1% |
| Fixed assets21/28 | €379,963 | €498,063 | €1.0m | €1.6m | €2.6m | ▲ 62.5% |
| Tangible fixed assets22/27 | €379,963 | €379,402 | €911,860 | €1.5m | €2.5m | ▲ 67.4% |
| Land and buildings22 | - | €377,461 | €372,085 | €366,710 | €370,511 | ▲ 1.0% |
| Plant, machinery and equipment23 | - | €912 | €1,938 | €1,313 | €688 | ▼ 47.6% |
| Furniture and vehicles24 | - | €1,030 | €1,838 | €1,376 | €23,821 | ▲ 1,631% |
| Leasing and similar rights25 | - | - | - | - | €163,034 | - |
| Assets under construction and advance payments27 | - | €0 | €535,999 | €1.1m | €2.0m | ▲ 72.6% |
| Financial fixed assets28 | - | €118,661 | €118,661 | €118,661 | €118,911 | ▲ 0.2% |
| Current assets29/58 | €186,328 | €302,325 | €159,099 | €268,268 | €295,934 | ▲ 10.3% |
| Amounts receivable after more than one year29 | - | €159,252 | €0 | - | - | - |
| Other amounts receivable291 | - | €159,252 | €0 | - | - | - |
| Amounts receivable within one year40/41 | €14,483 | €38,770 | €7,034 | €35,439 | €229,811 | ▲ 548% |
| Trade receivables40 | - | €38,745 | €6,829 | €24,611 | €24,880 | ▲ 1.1% |
| Other amounts receivable41 | - | €26 | €205 | €10,828 | €204,932 | ▲ 1,793% |
| Current investments50/53 | €16,647 | €17,539 | €18,440 | €19,278 | €0 | ▼ 100% |
| Cash at bank and in hand54/58 | €65,250 | €80,304 | €114,881 | €194,953 | €47,638 | ▼ 75.6% |
| Deferred charges and accrued income490/1 | - | €6,459 | €18,744 | €18,597 | €18,486 | ▼ 0.6% |
| Equity and liabilities | ||||||
| Total equity and liabilities10/49 | €566,291 | €800,389 | €1.2m | €1.9m | €2.9m | ▲ 55.1% |
| Equity10/15 | €211,118 | €342,375 | €463,300 | €595,372 | €710,179 | ▲ 19.3% |
| Contributions10/11 | - | €18,600 | €18,600 | €18,600 | €18,600 | = |
| Reserves13 | €192,518 | €323,775 | €444,700 | €576,772 | €691,579 | ▲ 19.9% |
| Distributable reserves133 | - | €323,775 | €444,700 | €576,772 | €691,579 | ▲ 19.9% |
| Profit (loss) carried forward14 | - | €0 | €0 | €0 | - | - |
| Amounts payable17/49 | €355,173 | €458,013 | €726,320 | €1.3m | €2.2m | ▲ 71.5% |
| Amounts payable after more than one year17 | €283,470 | €258,289 | €492,165 | €1.0m | €1.9m | ▲ 84.5% |
| Financial debts170/4 | - | €258,289 | €492,165 | €1.0m | €1.9m | ▲ 84.5% |
| Amounts payable within one year42/48 | €71,702 | €84,702 | €124,637 | €168,351 | €234,040 | ▲ 39.0% |
| Current portion of amounts payable after more than one year42 | - | €33,484 | €63,880 | €101,155 | €153,390 | ▲ 51.6% |
| Financial debts43 | - | €2,339 | €3,233 | €1,863 | €1,388 | ▼ 25.5% |
| Credit institutions430/8 | - | €2,339 | €3,233 | €1,863 | €1,388 | ▼ 25.5% |
| Trade debts44 | €19,096 | €6,641 | €10,922 | €42,764 | €60,436 | ▲ 41.3% |
| Suppliers440/4 | - | €6,641 | €10,922 | €42,764 | €60,436 | ▲ 41.3% |
| Taxes, remuneration and social security45 | - | €42,238 | €32,107 | €22,569 | €18,827 | ▼ 16.6% |
| Taxes450/3 | - | €42,238 | €32,107 | €22,569 | €18,827 | ▼ 16.6% |
| Other amounts payable47/48 | - | €0 | €14,495 | €0 | - | - |
| Accrued charges and deferred income492/3 | - | €115,022 | €109,518 | €103,164 | €97,219 | ▼ 5.8% |
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | Change |
|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €128,300 | €131,257 | €121,725 | €132,072 | €114,807 | ▼ 13.1% |
| + Depreciation and write-downs630 | €18,741 | €12,235 | €16,155 | €33,512 | €92,280 | ▲ 175% |
| Operating cash flow (approximation) | €147,041 | €143,492 | €137,879 | €165,585 | €207,087 | ▲ 25.1% |
| Investment in fixed assets (approximation) | - | -€130,335 | -€548,613 | -€633,468 | -€1.1m | ▼ 75.4% |
| Change in cash | - | €15,055 | €34,576 | €80,073 | -€147,316 | ▼ 284% |
Simplified and derived: a Belgian filing has no cash-flow statement, so these rows come from the income statement and the balance-sheet moves.
Timeline · acts, filings and financial milestones
2025
30-09
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema · 61 days late
2024
30-08
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema · 30 days late
2023
31-12
Financial
Highest result since 2019net €132,072 ▲8.5%
Operating result €189,502, net result €132,072, both a record.
31-12
Financial
Equity above €500,000Eq €595,372 ▲28.5%
5 profitable years in a row build equity to €595,372.
10-10
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema · 71 days late
2022
16-11
NBB filing
Annual accounts filed
fiscal year 2021 · micro schema · 108 days late
2021
08-10
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema · 69 days late
2020
28-01
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2019
30-01
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
2018
01-02
NBB filing
Annual accounts filed
fiscal year 2017 · micro schema · 1 day late
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
0 of 3 acts read
About the unread acts
We know of 3 Belgian State Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.
Directors · office · real estate
Directors
3 acts for this company are in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Waasmunster · 1 establishment unit since 2016
Ground area
4,305 m²
Building footprint
211 m²
Volume, LiDAR
2,197 m³
Parcel 42023B0648/00A000, Flanders · tallest building 22.4 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
SPARK CRC
since 20162.252.228.845
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 42023B0648/00A000 | Flanders | 4,305 m² | 1 · 211 m² | 22.4 m · 3 fl. |
Linked by address, not proof of ownership
Good to know
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
Dr. Lins - Dr. Dubois
BE 0871.844.215
Antwerpen · Eq €687,163
XeroThera Europe
BE 0697.932.717
Liège · Eq €646,920
MeiraGTx Belgium
BE 0765.235.968
Gent · Eq €615,562
DeuterOncology
BE 0754.971.388
Liège · Eq €965,547
Joos Clinical Projects
BE 0821.076.789
Destelbergen · Eq €519,440
Of 148 companies in sector 21100 we hold annual accounts for 108. 72 are within a factor 10 of this equity. The 5 above are the closest to it. See the whole sector
Identification & contact
Identification
Legal formPrivate limited company
Founded15-04-2016
Fiscal year end31-12
Activities, NACEBEL 2025
21100Manufacture of basic pharmaceutical products and pharmaceutical preparations
62200Computer consultancy and computer facilities management
68201Renting and operating of own or leased residential real estate, excluding social housing
70200Business and other management consultancy
73200Market research and public opinion polling
86910Medical imaging and medical laboratories
E-invoicing
Reachable via Peppol
Peppol ID
0208:0651972137
Also
9925:BE0651972137
Registered
21-10-2025
If you follow this company, Checked tells you the day it leaves the Peppol register.
Register as of 30 September 2026 · Peppol Directory
Scores and ratios are computed by Checked and are not a credit decision.